FDO Partners LLC Buys Shares of 24,910 Quest Diagnostics Inc (DGX)
FDO Partners LLC bought a new position in Quest Diagnostics Inc (NYSE:DGX) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 24,910 shares of the medical research company’s stock, valued at approximately $2,333,000. Quest Diagnostics comprises 0.9% of FDO Partners LLC’s portfolio, making the stock its 24th largest holding.
Several other institutional investors and hedge funds have also bought and sold shares of DGX. US Bancorp DE raised its holdings in shares of Quest Diagnostics by 0.9% in the 2nd quarter. US Bancorp DE now owns 18,065 shares of the medical research company’s stock worth $2,008,000 after acquiring an additional 156 shares during the last quarter. IBM Retirement Fund raised its holdings in shares of Quest Diagnostics by 28.3% in the 2nd quarter. IBM Retirement Fund now owns 2,020 shares of the medical research company’s stock worth $225,000 after acquiring an additional 445 shares during the last quarter. Harbour Capital Advisors LLC raised its holdings in shares of Quest Diagnostics by 11,016.0% in the 2nd quarter. Harbour Capital Advisors LLC now owns 63,361 shares of the medical research company’s stock worth $570,000 after acquiring an additional 62,791 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Quest Diagnostics by 6.1% in the 2nd quarter. Janney Montgomery Scott LLC now owns 8,726 shares of the medical research company’s stock worth $970,000 after acquiring an additional 499 shares during the last quarter. Finally, Eagle Global Advisors LLC acquired a new stake in shares of Quest Diagnostics in the 2nd quarter worth about $208,000. Institutional investors own 89.20% of the company’s stock.
DGX has been the topic of a number of analyst reports. Zacks Investment Research lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. BidaskClub lowered shares of Quest Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, August 9th. Morgan Stanley increased their price objective on shares of Quest Diagnostics from $87.00 to $92.00 and gave the company an “underweight” rating in a research note on Thursday, August 10th. ValuEngine upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $118.00 price objective on shares of Quest Diagnostics in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $106.28.
Quest Diagnostics Inc (NYSE:DGX) traded up $1.13 during trading on Friday, hitting $98.46. 3,487,600 shares of the stock were exchanged, compared to its average volume of 1,007,577. Quest Diagnostics Inc has a 1 year low of $86.89 and a 1 year high of $112.96. The company has a market cap of $13,480.00, a P/E ratio of 16.73, a P/E/G ratio of 1.95 and a beta of 0.59. The company has a quick ratio of 1.37, a current ratio of 1.47 and a debt-to-equity ratio of 0.78.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.35 by $0.04. Quest Diagnostics had a net margin of 8.82% and a return on equity of 15.53%. The firm had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.92 billion. During the same period in the prior year, the firm earned $1.37 EPS. The company’s revenue was up 2.4% compared to the same quarter last year. research analysts expect that Quest Diagnostics Inc will post 5.65 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Stockholders of record on Tuesday, January 9th will be given a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.83%. The ex-dividend date is Monday, January 8th. Quest Diagnostics’s dividend payout ratio is currently 37.50%.
ILLEGAL ACTIVITY WARNING: “FDO Partners LLC Buys Shares of 24,910 Quest Diagnostics Inc (DGX)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/01/fdo-partners-llc-buys-shares-of-24910-quest-diagnostics-inc-dgx.html.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).
Receive News & Stock Ratings for Quest Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Inc and related stocks with our FREE daily email newsletter.